--- title: "U.S. stock market midday update: OSR Holdings stock price skyrockets 47.04%, global licensing agreement sparks market optimism" type: "News" locale: "en" url: "https://longbridge.com/en/news/284787378.md" description: "OSR rose by 47.04%; AbbVie rose by 3.78%, with a transaction volume of USD 238 million; KalVista Pharmaceuticals had a transaction volume of USD 996.1 million; Alnylam Pharmaceuticals fell by 0.37%, with a transaction volume of USD 987.6 million; Amgen rose by 1.67%, with a market value of USD 185.5 billion" datetime: "2026-04-30T13:58:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284787378.md) - [en](https://longbridge.com/en/news/284787378.md) - [zh-HK](https://longbridge.com/zh-HK/news/284787378.md) --- # U.S. stock market midday update: OSR Holdings stock price skyrockets 47.04%, global licensing agreement sparks market optimism **U.S. Stock Market Midday Update** OSR rose 47.04%, with increased trading volume. Based on recent key news: 1. On April 29, OSR Holdings announced a global licensing agreement worth $815 million with BCM Europe, significantly boosting the stock price. The agreement involves the global licensing of VXM01, enhancing market confidence in the company's future growth. 2. On April 30, OSR Holdings plans to showcase the VXM01 licensing agreement at the Emerging Growth Conference on May 7, further elevating investor optimism about the company's prospects. This news continues to drive the stock price upward. 3. On April 29, forward-looking statements mentioned in OSR Holdings' press release attracted market attention. Despite risks and uncertainties, investors maintain a positive outlook on the company's future performance. The biopharmaceutical industry has been active recently, with high investor interest. **Top Stocks by Trading Volume in the Industry** AbbVie rose 3.78%. Based on recent key news: 1. On April 29, AbbVie raised its full-year earnings forecast due to strong sales of its immunology drugs Skyrizi and Rinvoq, driving first-quarter results above expectations. The company expects adjusted earnings per share of $14.08 to $14.28 for 2026, an upward revision from earlier guidance, leading to a 3.78% increase in stock price. Source: Barron's 2. On April 29, AbbVie reported first-quarter revenue of $15 billion, exceeding analyst expectations of $14.7 billion, with adjusted earnings per share of $2.65, higher than the expected $2.59, driving the stock price up. Source: RTTNews 3. On April 29, AbbVie's neuroscience product portfolio revenue grew 26% to $2.88 billion, outperforming expectations and further supporting the stock price increase. Source: RTTNews Strong demand for immunology drugs drives performance growth. KalVista Pharmaceuticals rose 38.62%. Based on recent key news: 1. On April 29, Italian pharmaceutical group Cassiopea announced a cash acquisition of KalVista Pharmaceuticals at $27 per share, with a total transaction value of approximately $1.9 billion. This news triggered a nearly 39% surge in KalVista's stock price, closing at $26.67. The transaction is expected to be completed in the third quarter of 2026, pending regulatory approval and majority shareholder voting support. 2. On April 30, KalVista Pharmaceuticals' stock price soared 38.62%, closing at $26.67, with an intraday high of $26.76 and trading volume reaching $1.904 billion, several times higher than the previous daily average. The technical indicators show typical event-driven violent surge characteristics, with market sentiment in an extremely euphoric state On April 29, Chiesi Group announced the acquisition of KalVista Pharmaceuticals to expand its global rare disease drug portfolio. This news triggered a high sensitivity in the market towards breakthroughs in innovative drug pipelines, leading to a significant increase in stock prices. The biotechnology sector has recently seen a notable increase in capital activity, with the market highly sensitive to breakthroughs in innovative drug pipelines. Alnylam Pharmaceuticals fell 0.37%. Based on recent key news: 1. On April 30, Alnylam Pharmaceuticals reported first-quarter net product revenue of $1.167 billion, exceeding market expectations of $1.115 billion. The company also reported strong operating income and adjusted net income, driving the stock price up. 2. On April 30, Alnylam Pharmaceuticals' TTR business revenue grew 153% year-over-year, with strong demand for AMVUTTRA, and the full-year revenue guidance was reaffirmed, demonstrating the company's strong performance in the market. 3. On April 29, analyst Patrick Trucchio reiterated a buy rating on Alnylam Pharmaceuticals and set a target price of $510, further boosting market confidence. The pharmaceutical industry is performing strongly overall, with significant capital inflows. **Stocks ranked among the top in industry market capitalization** Amgen rose 1.67%. Based on recent key news: 1. On April 28, the U.S. FDA proposed to withdraw the approval of Amgen's drug Tavneos due to its unproven efficacy and safety issues, including liver damage and death cases. This news caused stock price fluctuations, and Amgen stated it would respond to the FDA's decision. 2. On April 28, Amgen partnered with Paradigm Health to participate in the FDA's clinical trial data review reform project, aimed at accelerating the drug development process and improving safety oversight. 3. On April 28, analyst ratings showed Amgen with a hold rating and not included in the top five recommended buy stocks, with the market holding a cautious attitude towards its future performance. The biopharmaceutical industry faces regulatory challenges ### Related Stocks - [OSRH.US](https://longbridge.com/en/quote/OSRH.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [KALV.US](https://longbridge.com/en/quote/KALV.US.md) - [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md) - [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md) - [Motley Fool names Coca-Cola, P&G, J&J as 20-year dividend kings](https://longbridge.com/en/news/286957643.md) - [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md) - [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)